Full-thickness cartilage defects are repaired via a microfracture technique and intraarticular injection of the small-molecule compound kartogenin

Xingquan Xu1,2, Dongquan Shi1,2*, Yeshuai Shen1,2, Zihong Xu1, Jin Dai1,2, Dongyang Chen1, Huajian Teng2 and Qing Jiang1,2*

Abstract

Introduction: Microfracture does not properly repair full-thickness cartilage defects. The purpose of this study was to evaluate the effect of intraarticular injection of the small-molecule compound kartogenin (KGN) on the restoration of a full-thickness cartilage defect treated with microfracture in a rabbit model.

Methods: Full-thickness cartilage defects (3.5 mm in diameter and 3 mm in depth) were created in the patellar groove of the right femurs of 24 female New Zealand White rabbits. The rabbits were divided into two groups (12 in each group) based on postsurgery treatment differences, as follows: microfracture plus weekly intraarticular injection of KGN (group 1) and microfracture plus dimethyl sulfoxide (group 2). Six rabbits from each group were killed at 4 and 12 weeks after surgery, and their knees were harvested. The outcome was assessed both macroscopically, by using the International Cartilage Repair Society (ICRS) macroscopic evaluation system, and histologically, by using the modified O’Driscoll histologic scoring system. Immunohistochemistry for type II and I collagen was also conducted.

Results: At 4 weeks, group 1 showed better defect filling and a greater number of chondrocyte-like cells compared with group 2. At 12 weeks, group 1 showed statistically significantly higher ICRS scores and modified O’Driscoll scores compared with group 2. More hyaline cartilage-like tissue was found in the defects of group 1 at 12 weeks.

Conclusions: Intraarticular injection of KGN enhances the quality of full-thickness cartilage defects repair after microfracture, with better defect filling and increased hyaline-like cartilage formation.

Introduction

Full-thickness cartilage defects commonly occur and cannot heal spontaneously because of avascular and hypocellular processes; however, even focal cartilage defects progressively lead to the degeneration of the entire joint. To restore cartilage defects, various kinds of strategies have been developed [1-4]. Microfracture is one of the most common techniques used to treat full-thickness cartilage defects because of its low cost and simple method. After the subchondral bone is perforated to initiate bleeding, mesenchymal stem cells (MSCs) are recruited into the defects and differentiated into repair tissue. Both research types using rabbit models and short-term clinical studies have demonstrated that microfracture significantly relieves pain and improves knee function [5-7].

However, many researchers have observed that the long-term results after microfracture are poor and that microfracture is limited in treating cartilage defects in elderly patients. Von Keudel et al. [8] conducted a long-term follow-up study to evaluate the results of microfracture by using MRI scans and showed poor outcomes after an average of 48 months after surgery. A meta-analysis conducted by Mithoefer et al. [5] reported that the postoperation revision rate of the microfracture technique was approximately 2.5% at less than 24 months and increased to 2% to
31% at 24 months or longer after the operation. Indeed, microfracture does not generate pure hyaline cartilage. Specifically, the main repair tissue after microfracture is fibrocartilage, which primarily contains type I collagen [9-11]. Fibrocartilage is mechanically weaker than hyaline cartilage and degenerates easily [12,13]. To generate pure hyaline cartilage without fibrous and hypertrophic tissues in cartilage defects remains challenging.

Numerous studies have been conducted to enhance the hyaline quality of repair tissue in cartilage defects after microfracture surgery. Growth factors, platelet-rich plasma, and various types of scaffolds have been used to improve the repair quality after microfracture [14-17]. Positive effects were observed in the majority of these studies; however, no strategies exist that can fully replicate the biomechanical features of hyaline cartilage because the composition and organization of the repair tissue are insufficient [18]. Furthermore, several reagents and materials that were used in previous studies may even have adverse effects; therefore, novel strategies that can improve the repair quality after microfracture are still needed.

Recently, in a high-throughput screen, Johnson et al. [19] discovered a small molecule, kartogenin (KGN), that directs human bone marrow-derived mesenchymal stem cells (BMSCs) into chondrocytes by mediating the CBFβ-RUNX1 signaling pathway. Two osteoarthritis (OA) models, an acute surgical model, and a collagenase VII-induced model were used in their study to evaluate the repair effect of KGN in vivo. In this study, cartilage matrix regeneration was observed with intraarticular KGN administration. In our previous study, we found that KGN also has the potential to differentiate human synovium-derived mesenchymal stem cells (SMSCs) into chondrocytes. However, no studies have investigated the effect of intraarticular KGN injection on cartilage restoration after microfracture. The purpose of the present study was to evaluate the quality of cartilage-defects repair after microfracture with and without intraarticular KGN injection.

Methods

In total, 24 skeletally mature female New Zealand White rabbits weighing between 2.0 and 2.5 kg were used. All the rabbit procedures were approved by the Institutional Rabbit Care and Use Committee of Drum Tower Hospital, Medical School of Nanjing University. KGN was a kind gift from Nanjing Zhenquan Biosciences (Nanjing, China).

Surgical procedure

Each rabbit was anesthetized with an intramuscular injection of 5 mg droperidol and 0.1 g ketamine. In addition, anesthetization was maintained by slowly administering ketamine and diazepam through an auricular vein during the operation. The rabbit was placed in the supine position, and a medial parapatellar approach was used to operate on the right knee joint. Then, the patella was dislocated laterally to expose the articular surface. A full-thickness osteochondral defect (3.5 mm in diameter and 3 mm in depth) was made in the center of the trochlear groove by using an osteoarticular transplantation system. Then microfracture was performed with a 0.35 (0.9 mm) Kirschner wire (Figure 1A).

Postoperative treatment

After surgery, the rabbits were allowed free movement in their cages; their limbs were allowed to bear the entire body weight; and their general health status was monitored by a veterinarian.

KGN and DMSO administration

The rabbits were randomly divided into the following two groups: the experimental group (Group 1) and the control group (Group 2) (12 in each group). The KGN stock solution was prepared by directly dissolving KGN in DMSO, and the stock solution was diluted 10-fold with PBS to a concentration of 10 μM to prepare the working solution. In total, 0.3 ml of 10 μM KGN was injected into the operated-on joints of the rabbits in Group 1 once a week for 4 or 12 weeks. The control rabbits received an intraarticular injection of DMSO diluted 10-fold. The injection procedure was performed by using a 21-gauge needle and a superior-lateral approach by the same operator.

Macroscopic evaluation

The rabbits in each group were killed at 4 and 12 weeks (six rabbits at each time interval in each group), and the operated-on knees were harvested. The defect sites were photographed and blindly scored by three different investigators by using the International Cartilage Repair Society (ICRS) scoring system [20] (Table 1).

Histologic evaluation

After macroscopic evaluation, the specimens were fixed in 10% formalin for 7 days and decalcified in 15% ethylenediaminetetraacetate (EDTA)-buffered saline solution (Sunshine, Nanjing, China) for approximately 14 days. The specimens were dehydrated with serial ethanol, embedded in paraffin (Sigma), and cut into 5-μm sections. The sections were stained with toluidine blue (Sigma) and safranin O/Fast Green (Sigma) and viewed under a light microscope (Olympus, Japan). The sections were blindly scored by three different investigators by using a modified O’Driscoll histology scoring system [15,21] (Table 2).

Immunohistochemistry

Regarding the immunohistochemical staining, the sections were incubated with 0.4% pepsin at 37°C for 1 hour for
antigen retrieval. Endogenous peroxidase was blocked with 3% \( \text{H}_2\text{O}_2 \) in methanol for 30 minutes. To block nonspecific protein binding, 1% bovine serum albumin (BSA) solution (Sigma) was used. Monoclonal mouse anti-col II primary antibody (Calbiochem, Merck Millipore, 1:100 dilution) and anti-col I primary antibody (Abcam) were used to incubate the samples at 4°C overnight. Biotinylated secondary anti-mouse antibody (GE Healthcare; 1:500 dilution) was used to incubate the sections for 1 hour. The color reaction was developed with 3′,3′-diaminobenzidine (DAB) solution (Sigma), and 1% BSA solution was used as a control.

Data analysis
All the results are expressed as the mean ± standard deviation. The differences between the groups for macroscopic and histologic scores were analyzed with the unpaired \( t \) test, and a 95% confidence interval was also calculated. The significance was set at \( P \leq 0.05 \). All the data were analyzed by using SPSS software (version 20.0; IBM, USA).

Results
The health status of the rabbits
No rabbits died because of the surgical procedure or postoperative treatment, and all rabbits were able to load their limbs with no lameness. No evidence of surgery-related complications (e.g., joint or surgery site infection) was observed. No signs of adverse effects related to KGN injection were detected.

Macroscopic evaluation
At 4 weeks, repair tissue covered more than 50% of the cartilage defects in group 1; however, relatively little fibrous tissue was observed in group 2 (Figure 1B, C). At 12 weeks, the cartilage defects in group 1 were almost 100% filled with an obscure demarcation from surrounding cartilage (Figure 1D). However, in group 2, fibrous-like repair tissue covered approximately 80% of the defects with large penetrating cracks or fissures in many specimens (Figure 1E). At 12 weeks, the mean ICRS score for group 1 was 10.0 ± 1.1 compared with a mean score of 7.8 ± 1.3 for group 2 (\( P < 0.02 \)) (Table 3).

Histological evaluation of the full-thickness cartilage defects treated with microfracture and KGN
Histological analysis of the repair tissue in group 1 showed the formation of hyaline cartilage-like tissue. At 4 weeks, Toluidine blue staining revealed a larger amount of positively stained repair tissue in the defects in group 1 than in group 2 (Figure 2A, C). At 12 weeks, Toluidine blue staining (Figure 3) and Safranin O staining (Figure 4A, C and E) were used to assess the proteoglycans content in the repair tissue and showed three grades of intensity. Intense homogeneous staining of Toluidine blue and Safranin O at 12 weeks demonstrated that the defects in the majority

---

**Figure 1** Microfractured cartilage defect (A) and macroscopic appearance of the specimens in groups 1 (B, D) and 2 (C, E). Gross appearance was shown at 4 (B, C) and 12 weeks (D, E). (B) The repair tissue covered more than 50% of the cartilage defect. (C) Little repair tissue was observed in the cartilage defect. (D) Repair tissue almost completely covered the defect in the experimental group, but the defect in the control group (E) was insufficiently repaired.
of the specimens (5 of 6) were almost completely reconstructed (Figure 3; Figure 4A, C and E). Both the lateral and basal integration were satisfactory, and the subchondral bone was properly formed. In addition, well organized repair tissue was observed in the best repaired specimen (1 of 6) with nearly complete tidemark formation and nearly normal cell distribution. However, a penetrating crack was still detected in the repair tissue of the least repaired specimen (1 of 6).

Histological evaluation of the full-thickness cartilage defects treated with microfracture and DMSO

Histological analysis of group 2 showed no hyaline cartilage-like tissue formation. At 4 weeks, Toluidine blue staining (Figure 2B, D) showed that the defects were poorly covered by only fibrous-like tissue. At 12 weeks, both Toluidine blue (Figure 5) and safranin O (Figure 4B, D and F) slightly and heterogeneously stained the tissue. The demarcation between the repair tissue and the adjacent cartilage remained clear in all the samples. Subchondral bone formation was poor in the majority of the specimens (5 of 6). The repair tissue was also poorly organized, and no tidemark formation was observed. At 12 weeks, the histological scores (Table 4) in group 1 were significantly higher than those in group 2 for all the variables except for cartilage degeneration and basal integration, which did not show any significant differences between the two groups. Group 1 showed a significantly higher overall score than group 2 (18.5 ± 4.2 VS 8.3 ± 4.6, P < 0.01).

Immunohistochemistry

In group 1, repair tissue in the majority of the samples showed strong type II collagen staining (Figure 6A) and weak type I collagen staining (Figure 6C). In group 2, most of the samples were barely stained with type II collagen (Figure 6B), and intense type I collagen staining was observed (Figure 6D).

Discussion

This study shows that intra-articular injection of the small molecule KGN after microfracture results in significantly improved repair tissue in cartilage defects. Significant enhancements in the macroscopic ICRS and modified O’Driscoll scores were observed in the experimental group. In addition, the repair tissue that was generated in the presence of KGN showed the characteristics of hyaline cartilage with homogeneous Safranin O staining and strong type II collagen immunoreactivity. Importantly, no adverse effects were caused by the intra-articular KGN injection.

The macroscopic observation of the specimens showed that more repair tissue covered the defects in the experimental group. We speculate that the repair tissue differentiated from the MSCs in bone marrow, synovium or adipose tissue. These MSCs may be recruited into cartilage defects after microfracture [22-24]. Subsequent studies are needed to illuminate the precise roles that each type of MSC plays in repairing these defects. Although BMSCs are no longer enriched when the subchondral bone stops bleeding [25], other sources of MSCs, such as SMSCs in joint fluid, may be recruited during the cartilage repair process [26]. In a previous study, KGN was shown to recruit MSCs in the joint fluid to cartilage damage sites [19]. The intra-articular injection of KGN in our study may enrich MSCs in cartilage defects, which may result in a higher percentage of healing in the experimental group.

In the modified O’Driscoll histology scoring system, the experimental group obtained high scores related to multiple variables, such as the content of hyaline cartilage, the structure of the repair tissue and the reconstruction of the subchondral bone. These data may have resulted from the ability of KGN to promote chondrocyte differentiation from MSCs. Repair tissue and
### Table 2 The modified O’Driscoll histologic score

| Characteristic                                      | Grading                                      |
|-----------------------------------------------------|----------------------------------------------|
| I. % Hyaline cartilage                              | 80–100 Score                                 |
|                                                     | 60–80 8                                      |
|                                                     | 40–60 6                                      |
|                                                     | 20–40 4                                      |
|                                                     | 0–20 2                                       |
| II. Structural characteristics                      | Smooth and intact                            |
| A. Surface irregularity                             | Fissures 2                                   |
|                                                     | Severe disruption, fibrillation 1            |
| B. Structural integrity                             | Normal 0                                     |
|                                                     | Slight disruption, including cysts 2         |
|                                                     | Severe lack of integration 1                 |
| C. Thickness                                        | 100% of normal adjacent cartilage 0          |
|                                                     | 50% to 100% or thicker than normal 2         |
|                                                     | 0–50% 1                                      |
| D. Bonding to adjacent cartilage                    | Bonded at both ends of graft 0               |
|                                                     | Bonded at one end/partially both ends 2      |
|                                                     | Not bonded 1                                 |
| III. Freedom from cellular changes of degeneration  | Normal cellularity, no clusters 0            |
|                                                     | Slight hypocellularity, <25% chondrocyte clusters 2 |
|                                                     | Moderate hypocellularity, >25% clusters 1     |
| IV. Freedom from degenerate changes in adjacent cartilage | Normal cellularity, no clusters, normal staining 0 |
|                                                     | Normal cellularity, mild clusters, moderate staining 3 |
|                                                     | Mild or mod hypocellularity, slight staining 2 |
|                                                     | Severe hypocellularity, slight staining 1     |
| V. Reconstitution of subchondral bone               | Complete reconstitution 0                    |
|                                                     | Greater than 50% recon 2                     |
|                                                     | 50% or less recon 1                          |
| VI. Bonding of repair cartilage to de novo subchondral bone | Complete and uninterrupted 0               |
|                                                     | <100% but >50% recon 2                       |
|                                                     | <50% complete 1                              |
| VII. Safrinin O staining                            | >80% homogeneous positive stain 0            |
|                                                     | 40%–80% homogeneous positive stain 2         |
|                                                     | <40% homogeneous positive stain 1            |
|                                                     | Total score 0                                |
|                                                     | Max27                                        |

### Table 3 Results of macroscopic evaluation at 3 months

| Time periods     | Mean score ± SD | P value | 95% Confidence interval |
|------------------|-----------------|---------|-------------------------|
|                  | Group 1         | Group 2 |                         |
| Three months     | 10.0 ± 1.1      | 7.8 ± 1.3 | 0.012* | 0.60                       | 3.73                        |

*Statistically significant difference.
adjacent cartilage regeneration were minimal in group 1 compared with group 2; however, no significant difference was detected. These observations support the data from two previously developed OA models [19]. We postulate that KGN also plays a role in protecting existing chondrocytes. Overall, the efficiency of intra-articular KGN administration after microfracture may be attributable to both repair effect and protective effects.

Intra-articular injection of repair-promoting agents is a simple and less invasive procedure to improve repair tissue after microfracture. Recently, many reagents such as recombinant protein-based growth factors have been used to promote cartilage repair after microfracture [15]. Growth factors have been widely believed to have a strong potency in stimulating chondrogenesis [27,28]. However, small-molecule compounds possess obvious advantages towards recombinant protein-based growth factors. First, the cost and risk of cross-species contamination are significantly lower when using small molecules [29,30]. Second, low molecular weight therapeutics is too small (<1000 KDa) to induce an immune response [31]. These properties indicate that small molecule compounds are a potential alternative to growth factors in tissue regeneration [32,33].

The KGN concentration used in our study was 10 μM because data from our previous in vitro study showed that 10 μM KGN displays the greatest chondrogenesis potential without cytotoxicity. Based on the consideration that KGN sustainably induces MSCs recruited from joint fluid into chondrocytes, the injection procedure was not halted until the rabbits were sacrificed. Therefore, the two duration periods of the injection

Figure 2 Representative toluidine blue staining of the sections in experimental group (A, C) and control group (B, D) at 4 weeks. (A) Slightly stained repair tissue (R) covered more than 50% of the cartilage defect, although the surface was not smooth. At higher magnification (C), Toluidine blue staining of repair tissue (R) near native cartilage (C) was intense, and the integration was good. No tidemark formation was observed. (B) Negatively stained repair tissue (R) covered less than 50% of the cartilage defect. At higher magnification (D), only fibrous tissue was observed in the defect, and no tidemark formation was found. The left column images are magnified 20X, the right column images are magnified 100X.
Figure 3 Best, mean and worst results of toluidine blue staining in experimental group at 12 weeks. (A) The repair tissue (R) almost completely covered the cartilage defect flush with that of native cartilage (C). The thickness of the repair tissue was similar with that of the native tissue. At higher magnification (B), the demarcation between the repair tissue and the surrounding cartilage was almost undistinguishable. The repair tissue was well organized with nearly normal cell distribution. (C) The repair tissue (R) almost completely filled the cartilage defect. No fissures were observed. The repair tissue was thinner than adjacent healthy cartilage. At higher magnification (D), No clear clefs were observed between the repair tissue and the native cartilage, although the demarcation was still distinguishable. The organization of the repair tissue was poor. (E) Large cracks (arrow) were seen in the center of the repair tissue (R). At higher magnification (F), the integration between the repair tissue and the adjacent cartilage was good. The left column images are magnified 20X, and the right column images are magnified 100X.
Figure 4 Best, mean and worst results of safranin O staining in experimental (A, C and E) and control group (B, D and F) at 12 weeks.

(A) The repair tissue showed homogenous intense safranin O staining. Tidemark formation was observed, and subchondral bone formation was good. The surface was not smooth, with fibrous tissue existing. 

(C) The staining of the repair tissue was homogenously intense. No tissues or cracks were seen. But, no tidemark formation was observed. 

(E) Subchondral bone formation was poor with a large crack in the center of the repair tissue. But, safranin O staining was still intense in the extracellular matrix (ECM) of the repair tissue. No tidemark formation was found. 

(B) The ECM of the repair tissue was stained slightly and heterogeneously. The surface was not regular. No tidemark formation was seen. 

Subchondral bone formation was not good. 

(D) The repair tissue was stained negatively. No tidemark formation was seen, and subchondral bone formation was poor. 

(F) Little subchondral bone was seen. Safranin O staining was negative in the ECM of the repair tissue. All the magnification was 20X.
Figure 5 Best, mean and worst results of toluidine blue staining in control group at 12 weeks. (A) The cartilage defect was almost fully covered by repair tissue (R), but poor tuluidine blue staining was observed. At higher magnification (B), the demarcation between the repair tissue and the surrounding cartilage (C) was clear, although no clefs were observed. The organization of the repair tissue was poor with no typical cell distribution. (C) Clear crack or a poorly organized repair tissue (R) was observed in the defect. Subchondral bone formation was poor. At higher magnification (D), the integration was slight, and the organization of the repair tissue was poor with no typical cell distribution. (E) Membrane-like and negatively stained repair tissue (R) covered the defect. At higher magnification (F), no integration was observed. No chondrocyte-like cells were seen. The left column images are magnified 20X, and the right column images are magnified 100X.
Table 4 Results of histological evaluation at 3 months

| Variable                                      | Group 1   | Group 2   | P value | 95% Confidence interval |
|-----------------------------------------------|-----------|-----------|---------|-------------------------|
| % Hyaline cartilage                           | 4.7 ± 3.0 | 1.0 ± 1.1 | 0.019*  | 0.75 - 6.58             |
| Structural characteristics                    | 6.0 ± 0.6 | 3.2 ± 2.0 | 0.009*  | 0.89 - 4.78             |
| Freedom from cellular changes of degeneration  | 1.8 ± 0.4 | 1.2 ± 1.0 | 0.156   | -0.30 - 1.64            |
| Freedom from degenerate changes in adjacent cartilage | 1.7 ± 0.8 | 1.3 ± 0.5 | 0.419   | -0.55 - 1.21            |
| Reconstitution of subchondral bone            | 1.5 ± 0.6 | 0.5 ± 0.6 | 0.010*  | 0.30 - 1.71             |
| Bonding of repair cartilage to de novo subchondral bone | 1.5 ± 0.6 | 0.8 ± 0.8 | 0.110   | -0.18 - 1.53            |
| Safrinin O staining                           | 1.3 ± 0.8 | 0.3 ± 0.5 | 0.030*  | 0.12 - 1.88             |
| Total                                         | 18.5 ± 4.2| 8.3 ± 4.6 | 0.003*  | 4.46 - 15.87            |

*Statistically significant difference.

Figure 6 Immunohistochemical staining of the sections in experimental (A, C) and control group (B, D) at 12 weeks. Type I and II collagen was visualized by DAB (brown) staining. (A) The staining of type II collagen in repair tissue (R) was strong and similar with that of adjacent cartilage (C). (B) The matrix of the repair tissue (R) was stained slightly. (C) Almost no type I collagen staining was detected in the repair tissue (R) of group 1. (D) Intense type I collagen staining was observed in repair tissue (R) of group 2. All the images are magnified 20X.
procedure was 4 and 12 weeks. KGN was injected once a week to maintain an effective concentration in the knee joint; however, the precise concentration of KGN in knee joint was not monitored, which is the primary shortcoming of the present study. Future work should focus on identifying the best frequency and duration of KGN injection to promote tissue repair.

Conclusions

In conclusion, intra-articular KGN injection enhances the quality of full-thickness cartilage defect repair after microfracture.

Abbreviations

BMCSCs: Bone marrow-derived mesenchymal stem cells; DAB: Diaminobenzidine; ECM: Extracellular matrix; EDTA: Ethylenediaminetetraacetic acid; KGN: Kartogenin; MSCC: Mesenchymal stem cells; OA: Osteoarthritis; SNMGs: Synoviul-derived mesenchymal stem cells.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

XQX participated in the experimental design, carried out animal surgeries, KGN injections, histological staining, immunohistochemistry staining, analyzed the data, and drafted the manuscript. DQS contributed to conception of the study, experimental design, analyzed the data and drafted the manuscript. YSS helped with the animal surgeries, histological staining and to draft the manuscript. ZHX contributed to conception of the study, experimental design, analyzed the data, and revised the manuscript. All authors have read and approved the final manuscript.

Acknowledgement

This work was supported by the National Nature Science Foundation of China (81172513, 81101338) (to D.S. and Q.J.) and the Distinguished Young Investigator Project of Nanjing (to D.S.).

Received: 1 August 2014 Accepted: 22 January 2015 Published online: 02 February 2015

References

1. Chen FS, Frenkel S, Di Cesare P. Repair of articular cartilage defects: part II. Treatment options. Am J Orthop (Belle Mead NJ). 1999;28:88–96.
2. Steadman JR, Rodkey WG, Singleton SB, Briggs KK. Microfracture technique for full-thickness chondral defects: Technical and clinical results. Oper Tech Orthop. 1997;7:300–4.
3. Krusche-Mandl I, Schmitt B, Zak L, Apprich S, Aldrian S, Juras V, et al. Long-term results 8 years after autologous osteochondral transplantation: 7 T gagCEST and sodium magnetic resonance imaging with morphological and clinical correlation. Osteoarthritis Cartilage. 2012;20:357–63.
4. Moreira-Texeira LS, Georgi N, Leitjen J, Wu L, Karpenin M. Cartilage tissue engineering. Endocr. Dev. 2011;21:102–15.
5. Mittheofer K, McAdams T, Williams RJ, Kreuz PC, Mandelbaum BR. Clinical efficacy of the microfracture technique for articular cartilage repair in the knee as an evidence-based systematic analysis. Am J Sports Med. 2009;37:2053–63.
6. Mittheofer K, Williams RJ, Warren RF, Potter HG, Spock CR, Jones EC, et al. The microfracture technique for the treatment of articular cartilage lesions in the knee. A prospective cohort study. J Bone Joint Surg. 2005;87:1911–20.
7. Kreuz P, Steinwachs M, Ergeleut C, Krause S, Konrad G, Uhl M, et al. Results after microfracture of full-thickness chondral defects in different compartments in the knee. Osteoarthritis Cartilage. 2006;14:1119–25.
8. Von Keudell A, Atzwanger J, Forster R, Resch H, Hoffelner T, Mayer W. Radiological evaluation of cartilage after microfracture treatment: A long-term follow-up study. Eur J Radiol. 2011;81:1618–24.
9. Fricbie DD, Oxford JT, Southwood L, Trotter GW, Rodkey WG, Steadman JR, et al. Early events in cartilage repair after subchondral bone microfracture. Clin Orthop Relat Res. 2003;407:215–27.
10. Furukawa T, Eyre D, Koide S, Glimcher M. Biochemical studies on repair cartilage resurfacing experimental defects in the rabbit knee. J Bone Joint Surg. 1980;62:79–89.
11. Steadman J, Rodkey W, Briggs K. Microfracture to treat full-thickness chondral defects: surgical technique, rehabilitation, and outcomes. J Knee Surg. 2002;15:170–6.
12. Gilbert JE. Current treatment options for the restoration of articular cartilage. Am J Knee Surg. 1997;11:42–6.
13. Steinwachs M, Guge T, Kreuz P. Marrow stimulation techniques. Injury. 2008;39:26–31.
14. Milano G, Sanna Passino E, Deru L, Careddu G, Manunta L, Manunta A, et al. The effect of platelet rich plasma combined with microfractures on the treatment of chondral defects: an experimental study in a sheep model. Osteoarthritis Cartilage. 2010;18:971–80.
15. Power J, Hendemier P, Guehring H, Getgood A, Henson F. Intra-articular injection of rFGF-18 improves the healing in microfracture treated chondral defects in an ovine model. J Orthop Surg. 2014;32:669–76.
16. Doral M, Bilge O, Batmaz G, Dornmez G, Turhan E, Demirel M, et al. Treatment of osteochondral lesions of the talarus with microfracture technique and postoperative hyaluronan injection. Knee Surg Sports Traumatol Arthrosc. 2012;20:1398–403.
17. Ergeleut C, Endres M, Neumann K, Morawietz L, Ringe J, Habershoch K, et al. Formation of cartilage repair tissue in articular cartilage defects pretreated with microfracture and covered with cell-free polymer-based implants. J Orthop Surg. 2009;27:553–60.
18. Gille J, Schuessl E, Wimmer J, Gellissen J, Schultz A, Behrens P. Mid-term results of autologous matrix-induced chondrogenesis for treatment of focal cartilage defects in the knee. Knee Surg Sports Traumatol Arthrosc. 2010;18:1456–64.
19. Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J, Bouchec LC, et al. A stem cell-based approach to cartilage repair. Science. 2012;336:717–21.
20. Van Den Borne M, Rajmakers N, Vanlaauw J, Vici J, de Jong S, Bellemans J, et al. International Cartilage Repair Society (ICRS) and Osteoarticular cartilage evaluation scores validated for use in Autologous Chondrocyte Implantation (ACI) and microfracture. Osteoarthritis Cartilage. 2007;15:1397–402.
21. O’Driscoll SW, Marx RG, Beaton DE, Miura Y, Gallay SH, Fitzsimmons JS. Validation of a simple histological-histochemical cartilage scoring system. Tissue Eng. 2001;7:313–20.
22. Zhang W, Chen J, Tao J, Jiang Y, Hu C, Huang L, et al. The use of type 1 collagen scaffold containing stromal cell-derived factor-1 to create a matrix environment conducive to partial-thickness cartilage defects repair. Biomaterials. 2013;34:713–23.
23. Shapiro F, Koide S, Glimcher M. Cell origin and differentiation in the repair of full-thickness defects of articular cartilage. J Bone Joint Surg. 1993;75:532–53.
24. Ergeleut C, Neumann K, Endres M, Habershoch K, Sitterng M, Kaps C. Regeneration of ovine articular cartilage defects by cell-free polymer-based implants. Biomaterials. 2007;28:5570–80.
25. Caplan AI. The mesengenic process. Clin Plast Surg. 1994;21:429–35.
26. Sekiya I, Ojima M, Suzuki S, Yamaga M, Horie M, Koga H, et al. Human mesenchymal stem cells in synovial fluid increase in the knee with degenerated cartilage and osteoarthritis. J Orthop Surg. 2012;20:943–9.
27. Khan IM, Francis L, Theobald PS, Perri S, Young RD, Prokopovich P, et al. In vitro growth factor-induced bio engineering of mature articular cartilage. Biomaterials. 2013;34:1478–87.
28. Lee CH, Cook JL, Beaton DE, Miura Y, Gallay SH, Fitzsimmons JS. Validation of a simple histological-histochemical cartilage scoring system. Tissue Eng. 2001;7:313–20.
29. Blaich G, Janssen B, Roth G, Saffeld J. Overview: differentiating issues in the Handbook of Pharmaceutical Biotechnology. 2007. p. 89–123.
32. WH Lo K, D Ulery B, Deng M, MAsh K, T Laurencin C. Current patents on osteoinductive molecules for bone tissue engineering. Recent Pat Biomed Eng. 2011;4:153–67.
33. Segar CE, E Ogle M, A Botchwey E. Regulation of angiogenesis and bone regeneration with natural and synthetic small molecules. Curr Pharm Des. 2013;19:3403–19.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit